NEW YORK, Sept. 28, 2005 (PRIMEZONE) -- NanoViricides, Inc. (Pink Sheets:NNVC) announced that its President, Dr. Anil Diwan, has been selected to present today to a group of select investors at the Connecticut Venture Group's Annual CVG Angel forum. Only thirty entrepreneurial businesses across all industries have been chosen by CVG this year. The Connecticut Venture Group is sponsored by some of the leading organizations in the financial community such as Lehman Brothers, Pricewaterhouse and others. The goal of the group is to assist the development of high growth enterprises through the promotion of capital formation in Connecticut. Information on the group can be found at their website, www.cvg.org and www.ctinnovations.org
The company plans to begin pre-clinical studies on its first nanoviricide drug, FluCide-I, its anti-influenza drug, on October 11th. The animal trials will be supervised by Dr. Krishna Menon, Chief Regulatory Officer for the Company.
About NanoViricides -- http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types: HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(tm) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. When a NanoViricide drug enters the patient's blood stream, each nanoscale micelle of the drug attacks and neutralizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus particle by the NanoViricide micelle, destroying it completely. The company plans to develop novel NanoViricide drugs first against HIV and Influenza, and anticipates that it will license the products to major pharmaceutical companies.
This press release contains forward-looking statements which reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.